WASHINGTON, March 25 (Reuters) - The U.S. Food and Drug Administration on Friday said:
* Agency approves Bristol-Myers Squibb drug ipilimumab for
advanced melanoma
* Shares rise 2 percent after FDA announces approval of melanoma drug
* 'Due to unusual and severe side effects' Bristol-Myers melanoma drug
will require steps to inform doctors and patients about risks
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Agency approves Bristol-Myers Squibb drug ipilimumab for
advanced melanoma
* Shares rise 2 percent after FDA announces approval of melanoma drug
* 'Due to unusual and severe side effects' Bristol-Myers melanoma drug
will require steps to inform doctors and patients about risks
(Company news desk in Washington; +1 202 898 8400, washington.newsroom@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.